Phase 3 results posted: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy — Hoffmann-La Roche
Why now
Thesis: Roche adjuvant bladder cancer data posted
Catalyst to watch: Regulatory review of adjuvant use
Main risk: Results may not support expanded approval
Why it matters
Adjuvant atezolizumab results in bladder cancer inform Roche's oncology label expansion prospects.
Details
Sponsor: Hoffmann-La Roche; Status: Active Not Recruiting; Conditions: Muscle-invasive Bladder Cancer; Interventions: Atezolizumab, Placebo, Signatera; Enrollment: 761 (actual); First posted: 2020-12-09; Results posted: 2026-09-28; NCT: NCT04660344
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-28 12:00 UTC